The antitumor drug mitomycin can cause hemolytic-uremic syndrome (HUS), a serious condition characterized by anemia, low platelets, and kidney failure. Patients receiving mitomycin require close monitoring for HUS development.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Observation:
Findings:
Implications: